Retrospective study of all deaths among people undergoing naltrexone treatment for opioid dependence retrieved from the National Coronial Information System, 2000-2017.
This project will assemble a retrospective observational cohort of people presenting to emergency department and hospital inpatient services with an acute alcohol harm and/or problematic alcohol use.
This project uses linked administrative data to examine the patterns of use of prescribed opioids, quantify the risks of adverse outcomes, and examine the population-level impact of changes to regulation and subsidy of opioids.
Retaining patients in buprenorphine treatment is essential in maximising treatment outcomes and minimising mortality risk. Delivery of treatment via novel depot buprenorphine products has the potential to enhance patient adherence and retention in treatment.
Tapentadol is a centrally acting opioid analgesic with dual mechanisms of action, specifically µ-opioid receptor agonist and noradrenaline reuptake inhibition. This dual action is thought to result in a lower dose required to produce a given level of analgesia.
We have developed a multidisciplinary global consortium of researchers who can provide independent high-quality evidence regarding the scale of illicit drug use, harms, access to services at country, regional and global levels, and build capacity for better data in these areas.
The practices of diversion and misuse of pharmaceutical stimulants give serious cause for concern due to their potential to increase the risk of drug toxicity, dependence, and serious adverse health consequences. These practices may be particularly harmful among illicit psychostimulant users.
The study will examine all cases of fatal stroke in Australia amongst young people (<45 years) over the period 2009-2016 to determine the role of psychostimulants in these events.
Substance use amongst adolescents (those in the age group of 10-19) is an important public health issue in many countries of the region.
This project will conduct the first-ever outpatient RCT to test the efficacy, safety and cost-effectiveness of the pharmaceutical cannabinoid nabiximols (Sativex®) for treating cannabis dependence.
